Temozolomide + WSD0922-FU for Brain Cancer

This trial explores whether adding a new drug, WSD0922-FU, to the standard treatment of temozolomide can more effectively slow the progression of glioblastoma, a specific type of brain cancer with certain genetic features (EGFR-mutant, IDH-wildtype). Temozolomide attacks cancer cell DNA to halt growth, while WSD0922-FU targets a protein that aids cancer growth. Individuals with this type of brain cancer, who have completed radiation and are managing side effects well, might be suitable candidates. As a Phase 2 trial, the research focuses on measuring the treatment's effectiveness in an initial, smaller group of participants.

The trial does not specify if you need to stop taking your current medications. However, you cannot have taken certain therapies like targeted therapies, EGFR inhibitors, or strong inducers and inhibitors of CYP3A within a specific time before joining. It's best to discuss your current medications with the trial team.

In past studies, patients with brain cancer have generally tolerated temozolomide well. Combining temozolomide with other treatments has improved survival rates for some patients. For example, adding temozolomide to radiation therapy increased the 10-year survival rate in adults with certain brain tumors.

WSD0922-FU is a newer treatment currently under study. Early research focuses on determining the optimal dose and understanding side effects for glioblastoma and other tumors. Although complete safety data is not yet available, the treatment has shown promise in reaching the brain and aiding in tumor treatment.

Researchers are excited about the combination of Temozolomide and WSD0922-FU for brain cancer because it introduces a novel approach by adding WSD0922-FU to the treatment regime. Unlike the standard care, which primarily uses Temozolomide alone, this combination targets the cancer cells with a dual mechanism, potentially enhancing the overall effectiveness. WSD0922-FU is administered in multiple phases within each cycle, which may help in consistently attacking the cancer cells and preventing them from developing resistance. This innovative combination approach could lead to better outcomes and more options for patients with brain cancer.

Research has shown that combining temozolomide with radiation therapy extends the lives of brain cancer patients. Specifically, studies found that 70% of patients survived 10 years with this combination, compared to 47% without temozolomide. In this trial, participants in Arm A will receive a combination of temozolomide and the new drug, WSD0922-FU, which has shown early promise in effectively reaching brain tumors. WSD0922-FU targets a protein called EGFR, which often aids tumor growth. Using WSD0922-FU with temozolomide might enhance its ability to slow the disease. Initial findings suggest this combination could outperform temozolomide alone, which is being tested in Arm B of this trial.¹²⁴⁶⁷